Compare KSPI & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KSPI | EXAS |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | Kazakhstan | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 11.0B |
| IPO Year | 2024 | N/A |
| Metric | KSPI | EXAS |
|---|---|---|
| Price | $79.31 | $101.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | ★ $113.00 | $77.94 |
| AVG Volume (30 Days) | 542.1K | ★ 11.0M |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.36 | N/A |
| EPS | ★ 10.48 | N/A |
| Revenue | ★ $6,665,289,776.00 | $3,082,033,000.00 |
| Revenue This Year | $39.99 | $19.40 |
| Revenue Next Year | $19.87 | $13.51 |
| P/E Ratio | $7.52 | ★ N/A |
| Revenue Growth | ★ 54.22 | 14.47 |
| 52 Week Low | $70.61 | $38.81 |
| 52 Week High | $111.45 | $101.95 |
| Indicator | KSPI | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 62.39 | 87.70 |
| Support Level | $74.98 | $101.30 |
| Resistance Level | $77.77 | $101.93 |
| Average True Range (ATR) | 2.12 | 0.34 |
| MACD | 0.42 | -1.29 |
| Stochastic Oscillator | 80.11 | 53.50 |
Kaspi.kz JSC is the payment, marketplace, and Fintech ecosystem in Kazakhstan. The firm provides interconnected technologically seamless products and services that help people to pay, shop and manage their finances. Its operating segment includes the Payments Platform that connects its customers, which consist of both consumers and merchants, to facilitate cashless, digital transactions, the Marketplace Platform that connects merchants and consumers enabling merchants to increase their sales and consumers to buy a broad selection of products and services offered by a variety of merchants, and Fintech Platform that enables customers to manage their personal finances online and access consumer finance and deposit products through the Kaspi.kz Super App.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.